US8816242098 - ADR
TEVA PHARMACEUTICAL-SP ADR
NYSE:TEVA (3/28/2024, 8:04:00 PM)
After market: 14.11 0 (0%)14.11
-0.32 (-2.22%)
Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. The firm operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
TEVA PHARMACEUTICAL-SP ADR
5 Bazel St, P O B 3190
Petah Tikva 49131
P: 97239267267
CEO: Kare Schultz
Employees: 34004
Website: https://www.tevapharm.com/
Shares of UroGen Pharma (URGN) fell after Teva Pharma (TEVA) filed for FDA approval of a generic version of URGN's bladder cancer therapy, Jelmyto. Read more here.
In a welcome move, drug maker Organon stock saw its Relative Strength Rating rise from 66 to 71 on Wednesday.
Ethereum price predictions are a hot topic on Monday as crypto traders wonder where the token will go after surpassing $3,000.
Salesforce stock is rising higher on Monday after CRM shares got an increased price target from Jefferies analysts this morning.
Teva Pharmaceutical stock is rising higher on Monday after partner company Alvotech got approval from the FDA for a Humira biosimilar.
Here you can normally see the latest stock twits on TEVA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: